Lumenis Be, Ltd. appears in the linked FDA records as the applicant for a single 510(k) submission, K241973, covering the SmartIPL_NI System. The filing was received on July 5, 2024, and decided on September 19, 2026, with a Substantially Equivalent (SESE) decision. The record places the device in Class II under 21 CFR 878.4810, the regulation for powered laser surgical instruments, with the General and Plastic Surgery advisory panel and product code GEX. The applicant address on the filing is 9 Hakidma Street, P.O. Box 426, Yokneam Industrial Park, Yokneam, Israel; that is a correspondence address in the submission, not a verified corporate headquarters. [1][2][5]
The documented 510(k) record
K241973 is a Traditional 510(k) reviewed by FDA rather than a third party, and the record notes that a summary is available. The decision description is Substantially Equivalent. The device is listed as the SmartIPL_NI System, and the openFDA fields associate it with the device name Powered Laser Surgical Instrument, device class 2, regulation number 878.4810, and the medical specialty description General, Plastic Surgery. The submission was received July 5, 2024, and the decision date is September 19, 2026. [1][2][5]
Independent database views of the same filing repeat the same identifiers: applicant Lumenis Be, Ltd., product code GEX, decision SESE, decision date September 19, 2026, device class 2, and advisory committee SU. One view frames other devices cleared under product code GEX as a screening cohort rather than a predicate determination, which is a useful caution when reading product-code neighbors. [7][9]
What the supplied collection shows
The supplied portfolio snapshot, retrieved November 20, 2026, links one record to this company, all under the 510(k) pathway, and the decision counts show one SESE decision. The record sample contains exactly that one entry, K241973, so the sample decision counts also show one SESE. These figures describe the supplied filings as of that retrieval date; they are not a measure of total company sales, total portfolio, or safety performance. [1]
No recall records appear in the supplied sample. That absence reflects the supplied data only and should not be read as a statement about the company's postmarket history. [1]
Company description and technology
Lumenis describes itself as developing minimally invasive, energy-based solutions for the Aesthetic and Vision markets, and states that it has operated for over 60 years. Its published treatment categories include aesthetic areas such as skin, hair removal, body, and hair loss, and vision areas such as dry eye, glaucoma, and retina. These are company-published descriptions attributed to Lumenis, not independently verified claims. [4][6]
On the technology side, Lumenis explains selective photothermolysis as targeting specific chromophores such as blood, melanin, or water with a chosen wavelength, and describes its IPL technology as using Optimal Pulse Technology (OPT) to control pulse shape. The SmartIPL_NI System name in the 510(k) record is consistent with an IPL-related device, but the public documents do not state the system's indications, components, or performance results. [8]
Related filings and limits of the record
A separate FDA letter addresses K250809 under regulation 21 CFR 878.4810 and product code GEX, with the same applicant contact. K250809 is separate from the one-record MedtechLedger portfolio sample. Its own FDA letter is the source for that submission’s specific decision scope. [3]
Ownership, parent entities, brand structure, and commercial availability of the SmartIPL_NI System are not established by the public documents and remain unknown. The filing address should not be treated as a verified headquarters, and the SESE decision is a regulatory clearance finding, not evidence of clinical outcomes. [1][3]


